Open AccessTherapeutic Drug Monitoring of Ganciclovir: Where Are We?
Author(s) -
Anne-Grete Märtson,
Angela Elma Edwina,
Hannah Yejin Kim,
Marjolein Knoester,
Daan Touw,
Marieke G G Sturkenboom,
JanWillem C. Alffenaar
Publication year - 2021
Publication title -
therapeutic drug monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 93
eISSN - 1536-3694
pISSN - 0163-4356
DOI - 10.1097/ftd.0000000000000925
Subject(s) - pharmacokinetics , ganciclovir , therapeutic drug monitoring , pharmacology , pharmacodynamics , medicine , population , dosing , valganciclovir , drug , human cytomegalovirus , virus , immunology , environmental health
Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such as myelosuppression, which often leads to therapy cessation. Underdosing, as an attempt to prevent side effects, can lead to drug resistance and therapy failure. Therapeutic drug monitoring (TDM) has been used to overcome these problems. The purpose of this narrative review was to give an overview of ganciclovir TDM, available assays, population pharmacokinetic models, and discuss the current knowledge gaps.